Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00130182 · ClinicalTrials.gov registry record · Phase 2
A Study in Pediatric Patients With Cystic Fibrosis Lung Disease
A Phase 2 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 2
- Development phase
- 13
- Enrollment target
NCT00130182 is a Phase 2 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 13 participants.
The verdict
NCT00130182, a Phase 2 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 13 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the safety and effectiveness of two dose strengths of study drug compared to placebo in pediatric patients with cystic fibrosis (CF).
Interventions
- DRUG denufosol tetrasodium (INS37217)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2005-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00130182
The ClinicalTrials.gov registry entry for NCT00130182 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which denufosol tetrasodium (INS37217) is the first listed.
NCT00130182 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00130182 about?
NCT00130182 is a clinical study titled "A Study in Pediatric Patients With Cystic Fibrosis Lung Disease". The purpose of this study is to investigate the safety and effectiveness of two dose strengths of study drug compared to placebo in pediatric patients with cystic fibrosis (CF).
What is the current status of trial NCT00130182?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 2005-08.
What interventions are being tested in trial NCT00130182?
The interventions under investigation include: denufosol tetrasodium (INS37217) (DRUG).
Who is sponsoring clinical trial NCT00130182?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.